RE:RE:Any comments on this from Leede's Doug Loe? It does sound like he's mis-understanding that but given he doesn't state his own multiple it's hard to say. It could just be that he thinks by picking 100mg/mm2 that THTX are at the cautious end of this equivalent estimate. Does it say what he thinks the multiple is anywhere else in the report?
Wino115 wrote: I belive one of our science experts once discussed how to convert what the PDC level attached means in relation to the normal IV administration levels. Revolved around the fact the peptide has two units attached and there's some sort of molecular weight conversion you have to do to make it an apples-to-apples conversion. I think Loe is not doing that so it's not the proper comparison. Sorry, can't get more specific but I think JFM is the molecular chemist that did those comps before.
SPCEO1 wrote: Thera provided an update on its Phase I solid tumor testing with TH-1902, indicating that it has likely identified a maximum (barely) tolerable dose that is at or above 420 mg per square meter of body surface area, and this observation motivated the decision to shift all future patient dosing to a lower level of 300 mg/m2. Thera indicated that this represents a 1.5x elevated dosing level over that commonly used for docetaxel itself in solid tumor chemotherapy, but in our review of the literature, it is far higher than that (docetaxel as a monotherapy tends to be administered initially in most tumor types at 75-to-100 mg/m2). Accordingly, we believe that dosing at or above 300 mg/m2 still reflects favorably on the tumor targeting pharmacology that conjugation to sortilin receptor-binding peptides confers in TH-1902. As stated above, the concept of incorporating sortilin biochemistry into TH-1902 for targeted chemotherapy still seems reasonable to us and we are optimistic that justification for us to ascribe formal market value to this program will be forthcoming.